340B for Specialty Pharmacies 2.0 – Vital, Uncertain, Misused
Uncertainty surrounding the future of the 340B program is causing specialty pharmacies (SPs) to re-think operational enhancements, specifically around patient adherence services. Biopharma companies relying on SPs for adherence support may be forced to fill operational gaps to ensure patient adherence.
Discover the latest trends in the 340B program landscape and its impact on specialty pharmacies. Identify which specialty pharmacies dominate the market and evaluate the strategies specialty pharmacies use to optimize 340B revenue. Determine how biopharma can better partner with specialty pharmacies to enhance business with 340B entities.
A full report with additional insights is available as part of the NAVLIN Insights subscription. Contact us at [email protected] for access and to learn more about NAVLIN by EVERSANA and our innovative market research solutions.